Spots Global Cancer Trial Database for cetuximab
Every month we try and update this database with for cetuximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck | NCT00402545 | Head and Neck N... | Cetuximab Docetaxel Cisplatin 5-Fluorouracil | 18 Years - | Dana-Farber Cancer Institute | |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer | NCT05930938 | Squamous Cell C... | Xevinapant Placebo cetuximab IMRT | 18 Years - 79 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | NCT00874848 | NSCLC | Imprime PGG Inj... Cetuximab Paclitaxel Carboplatin | 18 Years - 75 Years | HiberCell, Inc. | |
| A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | NCT00409565 | Head and Neck C... Squamous Cell C... | Cetuximab Bevacizumab | 18 Years - 98 Years | National Cancer Institute (NCI) | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | NCT02563002 | Colorectal Carc... | mFOLFOX6 FOLFIRI pembrolizumab bevacizumab cetuximab | 18 Years - | Merck Sharp & Dohme LLC | |
| Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | NCT00003809 | Head and Neck C... | cetuximab cisplatin | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Biomarkers in Patients With Head and Neck Cancer | NCT01466257 | Head and Neck C... | cetuximab cisplatin DNA analysis gene expression... mutation analys... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | NCT05104567 | Oesophageal Squ... Gastric Cancer Hepatocellular ... Colorectal Canc... Oesophageal Ade... | THOR-707 Pembrolizumab Cetuximab | 18 Years - | Sanofi | |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. | NCT04229459 | Esophageal Squa... | Cisplatin 5-FU Radiation thera... Cetuximab Nivolumab | 18 Years - | Rabin Medical Center | |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | NCT00134069 | Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | sorafenib tosyl... cetuximab irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer | NCT00640081 | Colorectal Canc... | cetuximab capecitabine fluorouracil leucovorin calc... oxaliplatin immunohistochem... laboratory biom... | 18 Years - 100 Years | Medical Research Council | |
| Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors | NCT01166035 | Solid Tumors | Lenalidomide Cetuximab | 18 Years - 80 Years | Medical University Innsbruck | |
| Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | NCT00537823 | Colorectal Canc... Metastases | Cetuximab Bevacizumab Leucovorin Oxaliplatin Fluorouracil | 18 Years - | Washington University School of Medicine | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | NCT02123381 | Locally Advance... | preoperative ra... cetuximab | 18 Years - 65 Years | Sichuan Cancer Hospital and Research Institute | |
| RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN | NCT01009346 | Head and Neck C... | RAD001 Cetuximab Cisplatin Carboplatin | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer | NCT00109850 | Esophageal Canc... | cetuximab cisplatin irinotecan hydr... radiation thera... | 18 Years - | SWOG Cancer Research Network | |
| Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | NCT06225622 | Metastatic Colo... | Irinotecan Lipo... Oxaliplatin 5-FU LV Bevacizumab Cetuximab | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | NCT00571740 | Colorectal Canc... | bevacizumab cetuximab fluorouracil leucovorin calc... oxaliplatin | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | NCT01025089 | Thymoma Thymic Carcinom... Clinical Masaok... | Cetuximab, Cisp... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) | NCT00311857 | Glioblastoma Mu... | Cetuximab Temozolomide Radiation thera... | 18 Years - 70 Years | Heidelberg University | |
| CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | NCT02675946 | Solid Tumors GI Cancer | CGX1321 Pembrolizumab encorafenib cetuximab | 18 Years - | Curegenix Inc. | |
| Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer | NCT00005076 | Colorectal Canc... | cetuximab irinotecan hydr... | 18 Years - | University of Alabama at Birmingham | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors | NCT01081808 | Neoplasms Tumors Solid Tumors Metastatic Canc... | EGFRBi-armed au... | 18 Years - | Roger Williams Medical Center | |
| Cetuximab in Head and Neck Cancer Patients | NCT03769311 | Head and Neck C... Squamous Cell C... | Cetuximab | 18 Years - | University of Wisconsin, Madison | |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03370276 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Head and Neck S... Squamous Cell C... Head and Neck C... | Nivolumab Cetuximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) | NCT03944252 | Squamous Cell A... | Avelumab Cetuximab | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy | NCT02753140 | Carcinoma, Squa... | Cetuximab radiation Docetaxel Cisplatin | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | NCT00085501 | Lung Cancer | cetuximab carboplatin paclitaxel | 18 Years - | SWOG Cancer Research Network | |
| Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer | NCT00871169 | Pancreatic Canc... | Irinotecan, oxa... | 18 Years - | New Mexico Cancer Care Alliance | |
| Reactivating NK Cells in Treating Refractory Head and Neck Cancer | NCT02507154 | Nasopharyngeal ... Head and Neck S... | Cetuximab + NK ... | 21 Years - | National University Hospital, Singapore | |
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC | NCT00492206 | Non Small Cell ... | Cetuximab | 18 Years - | University of Pittsburgh | |
| Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC | NCT00828841 | Non-Small Cell ... | Cetuximab Paclitaxel Carboplatin Gemcitabine Cisplatin | 18 Years - | Accelerated Community Oncology Research Network | |
| Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | NCT04561336 | Metastatic Colo... RAS Wild Type | Avelumab Cetuximab | 18 Years - | University of Campania "Luigi Vanvitelli" | |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) | NCT02999087 | HNSCC | Cetuximab avelumab Cisplatin IMRT | 18 Years - 80 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery | NCT00305877 | Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... | cetuximab gemcitabine hyd... capecitabine radiation thera... bevacizumab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer | NCT00042939 | Pancreatic Canc... | cetuximab docetaxel irinotecan hydr... | 18 Years - | Eastern Cooperative Oncology Group | |
| CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer | NCT00330746 | Advanced Non-Sm... | cetuximab gemcitabine gemcitabine cetuximab | 18 Years - | National Cancer Institute, Naples | |
| Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | NCT04278092 | Head and Neck S... | Paclitaxel Cetuximab | 18 Years - | Medical University of Vienna | |
| Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). | NCT02296203 | Metastatic Colo... | cetuximab irinotecan | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer | NCT00522665 | Colorectal Canc... | Irinotecan Cetuximab RAD001 | 18 Years - | Hoosier Cancer Research Network | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer | NCT01051167 | Metastatic Colo... | Cetuximab | 18 Years - | Universität Duisburg-Essen | |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | NCT02124707 | Head and Neck C... Squamous Cell C... | Cetuximab Paclitaxel Carboplatin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer | NCT01075048 | Metastatic Colo... | Tivantinib Placebo Cetuximab Irinotecan | 18 Years - | Daiichi Sankyo | |
| Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck | NCT00084318 | Head and Neck C... | cetuximab cisplatin docetaxel radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | NCT00835679 | Liver Metastase... Mucinous Adenoc... Mucinous Adenoc... Recurrent Colon... Recurrent Recta... Signet Ring Ade... Signet Ring Ade... Stage IV Colon ... Stage IV Rectal... | cetuximab dasatinib therapeutic con... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer | NCT00482222 | Colorectal Canc... Metastatic Canc... | cetuximab capecitabine fluorouracil leucovorin calc... oxaliplatin study of socioe... adjuvant therap... neoadjuvant the... quality-of-life... | 18 Years - | University of Southampton | |
| A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer | NCT00055419 | Colorectal Neop... | Cetuximab | 18 Years - | Eli Lilly and Company | |
| S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer | NCT02438722 | Recurrent Non-S... Stage IV Non-Sm... | Afatinib Dimale... Cetuximab Laboratory Biom... | - | SWOG Cancer Research Network | |
| Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours | NCT01161316 | Metastatic Colo... | mFOLFOX-6 + cet... 8 cycles of mFO... | 18 Years - 70 Years | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer | NCT03986541 | Colorectal Canc... | Immunohistochem... | 18 Years - | University of Leeds | |
| Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer | NCT00551759 | Esophageal Canc... | 5-Fluorouracil Oxaliplatin Cetuximab Docetaxel Surgery Radiotherapy | 18 Years - | Eastern Cooperative Oncology Group | |
| TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer | NCT01060423 | Colorectal Canc... | Cetuximab Irinotecan Irinotecan elut... | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer | NCT01051167 | Metastatic Colo... | Cetuximab | 18 Years - | Universität Duisburg-Essen | |
| Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer | NCT00719199 | Colorectal Canc... | IMO-2055 Cetuximab FOLFIRI | 18 Years - | EMD Serono | |
| Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy | NCT00004865 | Head and Neck C... | cetuximab cisplatin fluorouracil paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer | NCT00301028 | Head and Neck C... | Cetuximab Carboplatin Paclitaxel Conventional Su... Radiation Thera... | 16 Years - | M.D. Anderson Cancer Center | |
| MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab | NCT04554836 | Adenocarcinoma ... Adenocarcinoma ... | Cetuximab FOLFIRI | 18 Years - 99 Years | TheraOp | |
| Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer | NCT00955240 | Anal Cancer | cetuximab cisplatin fluorouracil laboratory biom... radiation thera... | 18 Years - 80 Years | UNICANCER | |
| Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer | NCT02177838 | Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage IV Squamo... Stage IVA Squam... Stage IVA Squam... Stage IVA Verru... Stage IVB Squam... Stage IVB Squam... Stage IVB Verru... Tongue Cancer | cetuximab cisplatin external beam r... laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Lapatinib and Cetuximab in Patients With Solid Tumors | NCT01184482 | Colorectal Canc... Lung Cancer Head and Neck C... | cetuximab and l... | 18 Years - | Georgetown University | |
| sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC | NCT04091867 | Squamous Cell C... | sEphB4-HSA with... Cetuximab Radiation Thera... | 18 Years - 100 Years | University of Colorado, Denver | |
| Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer | NCT04262635 | Colorectal Canc... | Cetuximab, Cape... Cetuximab | 18 Years - | Sun Yat-sen University | |
| Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors | NCT01217450 | Recurrent Colon... Recurrent Recta... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Unspecified Adu... | selumetinib cetuximab laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | NCT00134069 | Recurrent Colon... Recurrent Recta... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... | sorafenib tosyl... cetuximab irinotecan hydr... | 18 Years - | National Cancer Institute (NCI) | |
| Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | NCT05722327 | Colon Cancer Colorectal Canc... | MRTX849 Irinotecan Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | NCT01104922 | Squamous Cell C... | Cetuximab Stereotactic ra... | 18 Years - | University of Pittsburgh | |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | NCT01107639 | Adenocarcinoma ... Esophageal Canc... | cetuximab cisplatin docetaxel adjuvant therap... neoadjuvant the... | 18 Years - 75 Years | Swiss Group for Clinical Cancer Research | |
| Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | NCT05799443 | Colorectal Canc... | Tislelizumab Irinotecan Hydr... cetuximab SBRT | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | NCT01810913 | Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... | Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| NBTXR3 With or Without Cetuximab in LA-HNSCC | NCT04892173 | Locally Advance... Aged | NBTXR3 Cetuximab Radiation Thera... | 65 Years - | Nanobiotix | |
| Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | NCT02143622 | Head and Neck S... | LJM716 cetuximab | 18 Years - | Novartis | |
| A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma | NCT00733889 | Esophageal Carc... | cetuximab and c... | 18 Years - 70 Years | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | |
| Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer | NCT00591149 | Head and Neck C... Carcinoma, Squa... | Oxaliplatin Docetaxel Cetuximab | 18 Years - | University of Kansas Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
